Seattle-based VentriPoint Diagnostics, a company seeking to develop fast, accurate ways to diagnose heart problems, has raised $1.2 million out of a financing round that could be worth as much as $3 million, according to a regulatory filing. The company, led by CEO George Adams, is using ultrasound and MRI instruments to construct 3-D images of the heart, particularly in newborns with congenital heart defects, according to a technology description on the company’s website.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
